ICER Questions Cost Effectiveness Of Empliciti, Kyprolis, Ninlaro
This article was originally published in The Pink Sheet Daily
Executive Summary
Newer regimens for multiple myeloma confer clinical survival benefits, but their cost-to-effectiveness comparisons are unfavorable, group says.